Zymeworks Inc.

Other

Zymeworks Bc Inc.

Medimmune Limited

Var2 Pharmaceuticals Aps

The University of British Columbia

Centre for Drug Research and Development

Bradley John Hedberg

John Stephen Babcook

James R Rich

Geoffrey C Winters

Alexander Laurence Mandel

Tom Han Hsiao Hsieh

Elyse Marie Josée Bourque

Michael R Hughes

Calvin D Roskelley

Christopher John Bond

Kelly Marshall McNagny

Jan Peter Bergqvist

Pamela Megan Dean

Anna Von Rossum

Katherine Grace MacDonald

Ismael Samudio

Klas Ola Blixt

Diana Canals Hernaez

Jaspal Singh Kang

Vahe Bedian

Simon Thomas Barry

Qing Zhou

Mads Daugaard

Madeleine Dahlback

Ali El-Salanti

Kimberly Ashely Snyder

Kelley Marshall Mcnagny

Elyse Marie Bourque

Tom Han Hsieh

Tom Han Hsiao Hsie

Alexander L Mandel

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Cytotoxic and anti-mitotic compounds, and methods of using the same

The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.

Anti-podocalyxin antibodies and methods of using the same

The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. Antibodies specific for podocalyxin designated Ab1 and 3G2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said anti bodies for targeting tumour endothelial cells that express podocalyxin.

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.

VAR2CSA-drug conjugates

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I).

The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.

Targeted binding agents directed to KDR and uses thereof&#x2014;035

Growing community of inventors

Vancouver, Canada

Bradley John Hedberg